ArticleJournal of diabetes investigation2022
New-onset fulminant type 1 diabetes after severe acute respiratory syndrome coronavirus 2 vaccination: A case report.
Article in Journal of diabetes investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Autoimmune diabetes mellitus after COVID-19 vaccination in adult population: a systematic review of case reports.BMC endocrine disorders · 2023Pooled it
- Endocrine system after 2 years of COVID-19 vaccines: A narrative review of the literature.Frontiers in endocrinology · 2022Pooled it
- The impact of diabetes and obesity on the severity and mortality of SARS-CoV-2 infection.Journal of diabetes and metabolic disorders · 2025Review
- Review
- New-onset Fulminant Type 1 Diabetes Following COVID-19 Vaccination.Internal medicine (Tokyo, Japan) · 2025Article
- Fulminant Type 1 Diabetes Mellitus With Concomitant Coxsackievirus B6 Antibody Elevation and RNA-Based COVID-19 Vaccination: A Case Report and Review of the Literature.Clinical case reports · 2025Article
- New Onset of Type 1 Diabetes Mellitus Post-COVID-19 Vaccine.Journal of medical cases · 2024Article
- Review
- Type 1 diabetes mellitus following COVID-19 vaccination: a report of two cases and review of literature.Diabetology international · 2024Article
- Case of new-onset fulminant type 1 diabetes mellitus accompanied by autoimmune thyroid disease after SARS-CoV-2 infection.Diabetology international · 2024Article
- New-Onset Diabetes Mellitus in COVID-19: A Scoping Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Review
- Anti-GAD antibody-positive fulminant type 1 diabetes developed following SARS-CoV-2 vaccination.Diabetology international · 2023Article
- New-Onset Fulminant Type 1 Diabetes After SARS-CoV-2 Infection.Diabetes care · 2023Article
- Molecular Mimicry and HLA Polymorphisms May Drive Autoimmunity in Recipients of the BNT-162b2 mRNA Vaccine: A Computational Analysis.Microorganisms · 2023Article
- New-Onset Fulminant Type 1 Diabetes Following SARS-CoV-2 Protein Subunit Vaccine: A Case Report and Literature Review.Journal of Korean medical science · 2023Review
- Correlation between COVID-19 vaccination and diabetes mellitus: A systematic review.World journal of diabetes · 2023Article
- Update information on type 1 diabetes in children/adolescents and adults.Journal of diabetes investigation · 2023Article
- Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to?Vaccines · 2023Review
- Case report: Fulminant type 1 diabetes following paucisymptomatic SARS-CoV-2 infection during late pregnancy.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fulminant type 1 diabetes is characterized by a rapid progression of insulin deficiency triggered by viral infection. Here, we report a case of a 45-year-old Japanese woman with fulminant type 1 diabetes that developed 8 days after receiving messenger ribonucleic acid vaccine against severe acute respiratory syndrome coronavirus 2. She had been healthy and had no symptoms suggestive of viral infection before the vaccination. Laboratory tests showed exhaustion of insulin secretion and negative results for islet autoantibodies. Human leukocyte antigen genotype analysis showed the DRB1*04:05 and DQB1*04:01 alleles. This is the first case report of new-onset fulminant type 1 diabetes after severe acute respiratory syndrome coronavirus 2 vaccination, and suggests that a severe acute respiratory syndrome coronavirus 2 vaccine might trigger the onset of fulminant type 1 diabetes in susceptible individuals. However, a causal relationship remains to be identified, and further studies are required to determine the incidence of such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.